Mammoth Biosciences

company

About

Mammoth Biosciences develops novel CRISPR applications for disease detection, research, agriculture, biodefense, and more.

Details

Last Funding Type
Series D
Last Funding Money Raised
$150M
Industries
Biotechnology,Genetics,Health Diagnostics,Life Science
Founded date
Jan 1, 2017
Number Of Employee
101 - 250
Operating Status
Active
Also Known As
Mammoth Diagnostics,Apheleia Diagnostics

Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth Biosciences aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, and Cas14, Mammoth Biosciences can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in South San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng Capital and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.

Mammoth has also been working on developing a rapid COVID-19 test.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
7
$264.54M
Mammoth Biosciences has raised a total of $264.54M in funding over 2 rounds. Their latest funding was raised on Sep 9, 2021 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 9, 2021 Series D $150M 11 Redmile Group Detail
Nov 4, 2020 Series C $45M 7 Foresite Capital
NFX
Redmile Group
Detail
Jul 31, 2020 Grant 1 National Institutes of Health Detail
Jan 30, 2020 Series B $45M 9 Decheng Capital Detail
Jul 31, 2018 Series A $23M 10 Mayfield Fund Detail

Investments

Number of Investments
Number of Lead Investments
2
1
Mammoth Biosciences has made 2 investments. Their most recent investment was on Jan 3, 2022, when Wall raised $1M.
Date Company Name
Round Money Raised Industry Lead Investor
Jan 3, 2022 Wall
Seed $1M Blockchain
Sep 1, 2021 CredShields
Angel $300K Blockchain Yes

Investors

Number of Lead Investors
Number of Investors
9
26
Mammoth Biosciences is funded by 26 investors. Redmile Group and National Institutes of Health are the most recent investors.
Investor Name Lead Investor Funding Round
Redmile Group Yes Series D
National Institutes of Health Yes Grant
Bradley Horowitz Series D
Decheng Capital Series D
Foresite Capital Series D
Greenspring Associates Series D
Mayfield Fund Series D
NFX Series D
Plum Alley Investments Series D
Senator Investment Group Series D

Employee Profiles

Number of Employee Profiles
18
Mammoth Biosciences has 18 current employee profiles, including Employee Jesus Ching
Employee
Advisor
Executive
Board member